SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include: Third Quarter and Recent Highlights YARTEMLEA® (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-lethal complication of stem cell transplantation, generated gross revenue of $41.8 million in the third qua

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.